Established and emerging biomarkers of immunotherapy in renal cell carcinoma

Papers of special note have been highlighted as: • of interest

References

• 1. Martin SD, Bhuiyan I, Soleimani M, Wang G. Biomarkers for immune checkpoint inhibitors in renal cell carcinoma. J. Clin. Med. 12(15), 4987 (2023).
  Medline CASGoogle Scholar
• 2. Chen F, Zhang Y, Şenbabaoğlu Y et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell. Rep. 14(10), 2476–2489 (2016).
  Medline CASGoogle Scholar
• 3. Iacovelli R, Sternberg CN, Porta C et al. Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr. Drug Targets 16(2), 164–170 (2015).
  Medline CASGoogle Scholar
• 4. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 10(10), 992–1000 (2009).
  Medline CASGoogle Scholar
• 5. Motzer RJ, Escudier B, Mcdermott DF et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
  Medline CASGoogle Scholar
• 6. Motzer RJ, Tannir NM, Mcdermott DF et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378(14), 1277–1290 (2018).
  Medline CASGoogle Scholar
• 7. Wong JSL, Kwok GGW, Tang V et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer 9(2), (2021).
  Google Scholar
• 8. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27(3), 409–416 (2016).
  Medline CASGoogle Scholar
• 9. Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv. Exp. Med. Biol. 1248, 33–59 (2020).
  Medline CASGoogle Scholar
• 10. Maleki Vareki S, Garrigós C, Duran I. Biomarkers of response to PD-1/PD-L1 inhibition. Crit. Rev. Oncol. Hematol. 116, 116–124 (2017).
  MedlineGoogle Scholar
• 11. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4), 847–856 (2015).
  Medline CASGoogle Scholar
• 12. Xu W, Atkins MB, Mcdermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol 17(3), 137–150 (2020).
  Medline CASGoogle Scholar
• 13. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018).
  Medline CASGoogle Scholar
• 14. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
  Medline CASGoogle Scholar
• 15. Choueiri TK, Powles T, Burotto M et al. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384(9), 829–841 (2021).
  Medline CASGoogle Scholar
• 16. Samstein RM, Lee CH, Shoushtari AN et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202–206 (2019).
  Medline CASGoogle Scholar
• 17. Guida A, Sabbatini R, Gibellini L, De Biasi S, Cossarizza A, Porta C. Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: what are we looking for? Cancer Treat. Rev. 94, 102157 (2021).
  Medline CASGoogle Scholar
• 18. Czyzyk-Krzeska MF, Landero Figueroa JA, Gulati S et al. Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma. Genes (Basel) 12(3), 388 (2021).
  Medline CASGoogle Scholar
• 19. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 20. Paver EC, Cooper WA, Colebatch AJ et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumors: a guide to immunohistochemistry implementation and interpretation. Pathology 53(2), 141–156 (2021).
  Medline CASGoogle Scholar
• 21. Khunger M, Hernandez AV, Pasupuleti V et al. Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis. JCO Precis Oncol. 1, 1–15 (2017).
  MedlineGoogle Scholar
• 22. Carretero-González A, Lora D, Martín Sobrino I et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel) 12(7), 1945 (2020).
  Medline CASGoogle Scholar
• 23. Motzer R, Alekseev B, Rha SY et al. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384(14), 1289–1300 (2021).
  Medline CASGoogle Scholar
• 24. Callea M, Albiges L, Gupta M et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res. 3(10), 1158–1164 (2015).
  Medline CASGoogle Scholar
• 25. Motzer RJ, Rini BI, Mcdermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol. 33(13), 1430–1437 (2015).
  Medline CASGoogle Scholar
• 26. Yearley JH, Gibson C, Yu N et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin. Cancer Res. 23(12), 3158–3167 (2017).
  Medline CASGoogle Scholar
• 27. Rini BI, Powles T, Atkins MB et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393(10189), 2404–2415 (2019).
  MedlineGoogle Scholar
• 28. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N. Engl. J. Med. 377(25), 2500–2501 (2017).
  MedlineGoogle Scholar
• 29. Motzer RJ, Robbins PB, Powles T et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26(11), 1733–1741 (2020).
  Medline CASGoogle Scholar
• 30. Marchetti A, Rosellini M, Mollica V et al. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int. J. Mol. Sci. 22(12), 6237 (2021).
  Medline CASGoogle Scholar
• 31. Pichler R, Compérat E, Klatte T et al. Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope? Cancers (Basel) 11(3), (2019).
  Google Scholar
• 32. Motzer RJ, Rini BI, Mcdermott DF et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20(10), 1370–1385 (2019). • A study defining the association of sarcomatoid differentiation with enhanced responsiveness to immunotherapy.
  Medline CASGoogle Scholar
• 33. Powles T, Plimack ER, Soulières D et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 21(12), 1563–1573 (2020).
  Medline CASGoogle Scholar
• 34. Tannir NM, Signoretti S, Choueiri TK et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin. Cancer Res. 27(1), 78–86 (2021).
  Medline CASGoogle Scholar
• 35. D'costa NM, Cina D, Shrestha R et al. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. Sci. Rep. 10(1), 2026 (2020).
  MedlineGoogle Scholar
• 36. Yoshida T, Ohe C, Ikeda J et al. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J. Immunother. Cancer 9(9), e002922 (2021).
  MedlineGoogle Scholar
• 37. Gulati S, Vogelzang NJ. Biomarkers in renal cell carcinoma: are we there yet? Asian J. Urol. 8(4), 362–375 (2021).
  MedlineGoogle Scholar
• 38. Mano R, Duzgol C, Ganat M et al. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - an exploratory analysis. Urol. Oncol. 39(11), 791.e717–791.e724 (2021).
  Google Scholar
• 39. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539–542 (2011).
  Medline CASGoogle Scholar
• 40. Miao D, Margolis CA, Gao W et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359(6377), 801–806 (2018).
  Medline CASGoogle Scholar
• 41. Braun DA, Ishii Y, Walsh AM et al. Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 5(11), 1631–1633 (2019).
  MedlineGoogle Scholar
• 42. Dai J, Cui Y, Liang X et al. PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. Front. Genet. 13, 1066347 (2022).
  Medline CASGoogle Scholar
• 43. Kapur P, Peña-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 14(2), 159–167 (2013).
  Medline CASGoogle Scholar
• 44. Joseph RW, Kapur P, Serie DJ et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 120(7), 1059–1067 (2014).
  Medline CASGoogle Scholar
• 45. Li F, Aljahdali IaM, Zhang R, Nastiuk KL, Krolewski JJ, Ling X. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J. Exp. Clin. Cancer Res. 40(1), 254 (2021).
  Medline CASGoogle Scholar
• 46. Moreira M, Pobel C, Epaillard N, Simonaggio A, Oudard S, Vano YA. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist. 3(3), 454–471 (2020).
  Medline CASGoogle Scholar
• 47. Voss MH, Reising A, Cheng Y et al. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncol. 19(12), 1688–1698 (2018).
  MedlineGoogle Scholar
• 48. Chen R, Zhao WQ, Fang C, Yang X, Ji M. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers. J. Cancer 11(11), 3349–3356 (2020).
  Medline CASGoogle Scholar
• 49. Hakimi AA, Ostrovnaya I, Reva B et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19(12), 3259–3267 (2013).
  Medline CASGoogle Scholar
• 50. Zheng X, Lin J, Xiong J et al. SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy. BMC Cancer 23(1), 686 (2023).
  Medline CASGoogle Scholar
• 51. Liu Y, Gou X, Wei Z, Yu H, Zhou X, Li X. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma. Aging (Albany NY) 12(15), 15359–15373 (2020).
  Medline CASGoogle Scholar
• 52. Ho TH, Choueiri TK, Wang K et al. Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. Eur. Urol. Focus 2(2), 204–209 (2016).
  MedlineGoogle Scholar
• 53. Hagiwara M, Fushimi A, Matsumoto K, Oya M. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur. Urol. 81(2), 145–148 (2022).
  Medline CASGoogle Scholar
• 54. Lanillos J, Santos M, Valdivia C, Mora A, Rodríguez-Antona C. Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma. Eur. Urol. 82(3), 334–335 (2022).
  Medline CASGoogle Scholar
• 55. Pan YR, Wu CE, Wang YC et al. Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clin. Transl. Immunol. 9(7), e1145 (2020).
  Medline CASGoogle Scholar
• 56. Ricciuti B, Recondo G, Spurr LF et al. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin. Cancer Res. 26(15), 4135–4142 (2020).
  Medline CASGoogle Scholar
• 57. Rizvi H, Sanchez-Vega F, La K et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J. Clin. Oncol. 36(7), 633–641 (2018).
  Medline CASGoogle Scholar
• 58. Labriola MK, Zhu J, Gupta RT et al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J. Immunother. Cancer 8(1), e000319 (2020).
  MedlineGoogle Scholar
• 59. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13(7), 411–424 (2012).
  Medline CASGoogle Scholar
• 60. Pletcher JP, Bhattacharjee S, Doan JP et al. The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. Front. Oncol. 11, 681441 (2021).
  Medline CASGoogle Scholar
• 61. Ged G, Rifkind I, Tony L et al. ORCHID: a phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations. Oncologist 28(Suppl. 1), S1 (2023).
  MedlineGoogle Scholar
• 62. Hamada T, Soong TR, Masugi Y et al. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology 7(7), e1442999 (2018).
  MedlineGoogle Scholar
• 63. Jansen CS, Prokhnevska N, Master VA et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576(7787), 465–470 (2019).
  Medline CASGoogle Scholar
• 64. Eroglu Z, Zaretsky JM, Hu-Lieskovan S et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553(7688), 347–350 (2018).
  Medline CASGoogle Scholar
• 65. Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J. Gastroenterol. 25(24), 2977–2989 (2019).
  Medline CASGoogle Scholar
• 66. Kawashima A, Uemura M, Nonomura N. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma. Clin. Genitourin. Cancer 17(6), e1147–e1152 (2019).
  MedlineGoogle Scholar
• 67. Zhang S, Zhang E, Long J et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 110(5), 1564–1572 (2019).
  Medline CASGoogle Scholar
• 68. Yao J, Xi W, Zhu Y, Wang H, Hu X, Guo J. Checkpoint molecule PD-1-assisted CD8(+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Cancer Manag. Res. 10, 3419–3431 (2018).
  Medline CASGoogle Scholar
• 69. Nakano O, Sato M, Naito Y et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 61(13), 5132–5136 (2001).
  Medline CASGoogle Scholar
• 70. Carlisle JW, Jansen CS, Cardenas MA et al. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J. Immunother. Cancer 10(7), (2022). • A study describing a peripheral burst of activated CD8 T cells in patients with positive response to immunotherapy, as well as increased presence of intratumoral immune niches in patients with clinical benefit following immunotherapy.
  MedlineGoogle Scholar
• 71. Stenzel PJ, Schindeldecker M, Tagscherer KE et al. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Transl. Oncol. 13(2), 336–345 (2020).
  MedlineGoogle Scholar
• 72. Cristescu R, Mogg R, Ayers M et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362(6411), eaar3593 (2018).
  MedlineGoogle Scholar
• 73. Ascierto ML, Mcmiller TL, Berger AE et al. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. Cancer Immunol. Res. 4(9), 726–733 (2016).
  Medline CASGoogle Scholar
• 74. Wallin JJ, Bendell JC, Funke R et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016).
  Medline CASGoogle Scholar
• 75. Routy B, Le Chatelier E, Derosa L et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359(6371), 91–97 (2018).
  Medline CASGoogle Scholar
• 76. Salgia NJ, Bergerot PG, Maia MC et al. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors. Eur. Urol. 78(4), 498–502 (2020).
  Medline CASGoogle Scholar
• 77. Pal SK, Li SM, Wu X et al. Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors. Clin. Cancer Res. 21(23), 5286–5293 (2015).
  Medline CASGoogle Scholar
• 78. Derosa L, Hellmann MD, Spaziano M et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29(6), 1437–1444 (2018).
  Medline CASGoogle Scholar
• 79. Dizman N, Meza L, Bergerot P et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 28(4), 704–712 (2022).
  Medline CASGoogle Scholar
• 80. Shirasu M, Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J. Biochem. 150(3), 257–266 (2011).
  Medline CASGoogle Scholar
• 81. Van De Kant KD, Van Der Sande LJ, Jöbsis Q, Van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. Respir. Res. 13(1), 117 (2012).
  MedlineGoogle Scholar
• 82. Janfaza S, Khorsand B, Nikkhah M, Zahiri J. Digging deeper into volatile organic compounds associated with cancer. Biol. Methods Protoc. 4(1), bpz014 (2019).
  Medline CASGoogle Scholar
• 83. Lagniau S, Lamote K, Van Meerbeeck JP, Vermaelen KY. Biomarkers for early diagnosis of malignant mesothelioma: do we need another moonshot? Oncotarget 8(32), 53751–53762 (2017).
  MedlineGoogle Scholar
• 84. Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis. JAMA Oncol. 5(1), e182815 (2019).
  MedlineGoogle Scholar
• 85. De Vries R, Muller M, Van Der Noort V et al. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. Ann. Oncol. 30(10), 1660–1666 (2019).
  MedlineGoogle Scholar
• 86. Buma AIG, Muller M, De Vries R et al. eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. Lung Cancer 160, 36–43 (2021).
  Medline CASGoogle Scholar
• 87. Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response. https://clinicaltrials.gov/study/NCT04146064
  Google Scholar
• 88. Stone L. Urinary VOCs as bladder cancer biomarkers. Nat. Rev. Urol. 19(5), 256 (2022).
  Google Scholar
• 89. Murdocca M, Torino F, Pucci S et al. Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer. Cancers (Basel) 13(16), (2021).
  MedlineGoogle Scholar
• 90. Santoni M, Cortellini A, Buti S. Unlocking the secret of the obesity paradox in renal tumors. Lancet Oncol. 21(2), 194–196 (2020).
  MedlineGoogle Scholar
• 91. Cortellini A, Bersanelli M, Santini D et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur. J. Cancer 128, 17–26 (2020).
  Medline CASGoogle Scholar
• 92. Sanchez A, Furberg H, Kuo F et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 21(2), 283–293 (2020).
  Medline CASGoogle Scholar
• 93. Wang Z, Aguilar EG, Luna JI et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat. Med. 25(1), 141–151 (2019).
  Medline CASGoogle Scholar
• 94. Indini A, Rijavec E, Ghidini M et al. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. Int. J. Mol. Sci. 22(5), 2628 (2021).
  Medline CASGoogle Scholar
• 95. Martini DJ, Shabto JM, Goyal S et al. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. Oncologist 26(12), 1017–1025 (2021). • A study describing the potential of use of immune-related adverse events (irAE) occurrence as a clinical biomarker of therapeutic response to immune checkpoint blockade in patients with metastatic renal cell carcinoma.
  Medline CASGoogle Scholar
• 96. Martini DJ, Olsen TA, Goyal S et al. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. Front. Oncol. 11, 707050 (2021).
  Medline CASGoogle Scholar
• 97. Martini DJ, Kline MR, Liu Y et al. Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer 126(3), 575–582 (2020).
  Medline CASGoogle Scholar
• 98. Bilen MA, Martini DJ, Liu Y et al. Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. Oncologist 25(3), e528–e535 (2020).
  Medline CASGoogle Scholar
• 99. Bagley SJ, Kothari S, Aggarwal C et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106, 1–7 (2017).
  MedlineGoogle Scholar
• 100. Nunno VD, Mollica V, Gatto L et al. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy 11(7), 631–643 (2019).
  CASGoogle Scholar
• 101. Templeton AJ, Knox JJ, Lin X et al. Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. Eur. Urol. 70(2), 358–364 (2016).
  MedlineGoogle Scholar
• 102. Lalani AA, Xie W, Martini DJ et al. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J. Immunother. Cancer 6(1), 5 (2018).
  MedlineGoogle Scholar
• 103. Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol. 20(1), 90 (2020).
  Medline CASGoogle Scholar
• 104. Bilen MA, Rini BI, Voss MH et al. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clin. Cancer Res. 28(4), 738–747 (2022).
  Medline CASGoogle Scholar
• 105. Bilen MA, Dutcher GMA, Liu Y et al. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin. Genitourin. Cancer 16(3), e563–e575 (2018).
  MedlineGoogle Scholar
• 106. Ravindranathan D, Master VA, Bilen MA. Inflammatory Markers in Cancer Immunotherapy. Biology (Basel) 10(4), (2021).
  MedlineGoogle Scholar
• 107. Bilen MA, Martini DJ, Liu Y et al. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer 125(1), 127–134 (2019).
  MedlineGoogle Scholar
• 108. Martini DJ, Kline MR, Liu Y et al. Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. Cancer Treat. Res. Commun. 28, 100393 (2021).
  MedlineGoogle Scholar
• 109. Zhuang TZ, Ravindranathan D, Liu Y et al. Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist 28(3), 239–245 (2023).
  MedlineGoogle Scholar
• 110. Brown JT, Liu Y, Shabto JM et al. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. J. Immunother. Cancer 9(7), e002851 (2021).
  MedlineGoogle Scholar
• 111. Martini DJ, Liu Y, Shabto JM et al. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist 25(3), e484–e491 (2020).
  Medline CASGoogle Scholar
• 112. Smith CG, Moser T, Mouliere F et al. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med. 12(1), 23 (2020).
  Medline CASGoogle Scholar
• 113. Geertsen L, Koldby KM, Thomassen M, Kruse T, Lund L. Circulating Tumor DNA in Patients with Renal Cell Carcinoma. A Systematic Review of the Literature. Eur. Urol. Open Sci. 37, 27–35 (2022).
  MedlineGoogle Scholar
• 114. Hahn AW, Gill DM, Maughan B et al. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8(20), 33614–33620 (2017).
  MedlineGoogle Scholar
• 115. Pal SK, Sonpavde G, Agarwal N et al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur. Urol. 72(4), 557–564 (2017).
  Medline CASGoogle Scholar
• 116. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J. Hematol. Oncol. 15(1), 131 (2022).
  Medline CASGoogle Scholar
• 117. Zhang Q, Luo J, Wu S et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 10(12), 1842–1853 (2020).
  Medline CASGoogle Scholar
• 118. Yu T, Wang Y, Fan Y et al. CircRNAs in cancer metabolism: a review. J. Hematol. Oncol. 12(1), 90 (2019).
  MedlineGoogle Scholar
• 119. Qu S, Liu Z, Yang X et al. The emerging functions and roles of circular RNAs in cancer. Cancer Lett. 414, 301–309 (2018).
  Medline CASGoogle Scholar
• 120. Rashedi S, Mardani M, Rafati A et al. Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma. J. Clin. Lab. Anal. 36(10), e24670 (2022).
  Medline CASGoogle Scholar
• 121. Dong Y, Gao Q, Chen Y et al. Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy. Nat. Commun. 14(1), 2540 (2023).
  Medline CASGoogle Scholar
• 122. Franz A, Ralla B, Weickmann S et al. Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy. Cancers (Basel) 11(10), 1473 (2019).
  Medline CASGoogle Scholar
• 123. Cui X, Wang J, Guo Z et al. Emerging function and potential diagnostic value of circular RNAs in cancer. Mol. Cancer 17(1), 123 (2018).
  MedlineGoogle Scholar
• 124. Zhang S, Zhang F, Niu Y, Yu S. Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma. Cancer Manag. Res. 13, 6489–6497 (2021).
  MedlineGoogle Scholar
• 125. Zhou Y, Zhang Z, Wo M, Xu W. The long non-coding RNA NNT-AS1 promotes clear cell renal cell carcinoma progression via regulation of the miR-137/ Y-box binding protein 1 axis. Bioengineered 12(1), 8994–9005 (2021).
  Medline CASGoogle Scholar
• 126. Li T, Tong H, Zhu J et al. Identification of a Three-Glycolysis-Related lncRNA Signature Correlated With Prognosis and Metastasis in Clear Cell Renal Cell Carcinoma. Front. Med. (Lausanne) 8, 777507 (2021).
  MedlineGoogle Scholar
• 127. Su Y, Zhang T, Tang J et al. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Front. Oncol. 11, 640150 (2021).
  Medline CASGoogle Scholar
• 128. Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. MALAT1: a long non-coding RNA highly associated with human cancers. Oncol. Lett. 16(1), 19–26 (2018).
  MedlineGoogle Scholar
• 129. Hirata H, Hinoda Y, Shahryari V et al. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res. 75(7), 1322–1331 (2015).
  Medline CASGoogle Scholar
• 130. Zhai W, Ma J, Zhu R et al. MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis. Br. J. Cancer 119(5), 591–604 (2018).
  Medline CASGoogle Scholar
• 131. Jin C, Shi L, Li K et al. Mechanism of tumor-derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1. Oncol. Rep. 46(3), 187 (2021).
  Medline CASGoogle Scholar
• 132. Li Z, Ma Z, Xu X. Long non-coding RNA MALAT1 correlates with cell viability and mobility by targeting miR-22-3p in renal cell carcinoma via the PI3K/Akt pathway. Oncol. Rep. 41(2), 1113–1121 (2019).
  Medline CASGoogle Scholar
• 133. Guo R, Zou B, Liang Y et al. LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma. Cell Death Dis. 12(7), 689 (2021).
  Medline CASGoogle Scholar
• 134. Tan L, Tang Y, Li H et al. N6-Methyladenosine Modification of LncRNA DUXAP9 Promotes Renal Cancer Cells Proliferation and Motility by Activating the PI3K/AKT Signaling Pathway. Front. Oncol. 11, 641833 (2021).
  Medline CASGoogle Scholar
• 135. Nakken S, Eikrem Ø, Marti HP et al. AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease. Cancer Cell Int. 21(1), 690 (2021).
  Medline CASGoogle Scholar
• 136. Fu S, Gong B, Wang S et al. Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma. Int. J. Gen. Med. 14, 8047–8064 (2021).
  Medline CASGoogle Scholar
• 137. Han S, Qi Y, Xu Y et al. lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p. Cancer Cell Int. 21(1), 376 (2021).
  Medline CASGoogle Scholar
• 138. Dong P, Xiong Y, Konno Y et al. Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway. J. Exp. Clin. Cancer Res. 40(1), 216 (2021).
  Medline CASGoogle Scholar
• 139. Li K, Sun D, Gou Q et al. Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells. Cancer Lett. 420, 80–90 (2018).
  Medline CASGoogle Scholar
• 140. Yue QY, Zhang Y. Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer. Eur. Rev. Med. Pharmacol. Sci. 22(4), 1003–1010 (2018).
  MedlineGoogle Scholar
• 141. Meng X, Sun W, Yu J et al. LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer. Mol. Ther. Nucleic Acids 22, 1004–1015 (2020).
  Medline CASGoogle Scholar
• 142. Yu Y, Zhang W, Li A et al. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer. JAMA Netw. Open 3(4), e202149 (2020).
  MedlineGoogle Scholar
• 143. Deutsch JS, Lipson EJ, Danilova L et al. Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Rep. Med. 4(2), 100947 (2023). • A study proposing a multimodal approach to biomarker development, combining histology-based measurement of lymphocyte infiltration, presence of necrosis and PBRM1 mutational status.
  Medline CASGoogle Scholar
• 144. Mcdermott DF, Huseni MA, Atkins MB et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24(6), 749–757 (2018).
  Medline CASGoogle Scholar
• 145. Bi K, He MX, Bakouny Z et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 39(5), 649–661.e645 (2021).
  Medline CASGoogle Scholar
• 146. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7(1), 306 (2019).
  MedlineGoogle Scholar
• 147. Nukaya T, Takahara K, Yoshizawa A et al. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. Clin. Genitourin. Cancer doi: 10.1016/j.clgc.2023.09.007 (2023).
  Google Scholar
• 148. Ueda K, Suekane S, Kurose H et al. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn. J. Clin. Oncol. 52(5), 479–485 (2022).
  MedlineGoogle Scholar
• 149. Martini DJ, Goyal S, Liu Y et al. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist 26(10), e1742–e1750 (2021). • A study describing the potential of use of irAE occurrence as a clinical biomarker of therapeutic response to immune checkpoint blockade in patients with metastatic renal cell carcinoma.
  Medline CASGoogle Scholar
• 150. Washino S, Shirotake S, Takeshita H et al. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. Int. J. Clin. Oncol. 28(12), 1651–1658 (2023).
  Medline CASGoogle Scholar
• 151. Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8(69), 114268–114280 (2017).
  MedlineGoogle Scholar
• 152. Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J. Surg. Oncol. 20(1), 242 (2022).
  MedlineGoogle Scholar
• 153. Tasaki Y, Hamamoto S, Sugiyama Y et al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. Int. J. Urol. 30(10), 866–874 (2023).
  Medline CASGoogle Scholar
• 154. Ruste V, Goldschmidt V, Laparra A et al. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry. Eur. J. Cancer 158, 217–224 (2021).
  Medline CASGoogle Scholar
• 155. Michailidou D, Khaki AR, Morelli MP, Diamantopoulos L, Singh N, Grivas P. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci. Rep. 11(1), 9029 (2021).
  Medline CASGoogle Scholar
• 156. Eun Y, Kim IY, Sun JM et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep. 9(1), 14039 (2019).
  MedlineGoogle Scholar
• 157. Suazo-Zepeda E, Bokern M, Vinke PC, Hiltermann TJN, De Bock GH, Sidorenkov G. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol. Immunother. 70(11), 3069–3080 (2021).
  Medline CASGoogle Scholar
• 158. Lee PY, Oen KQX, Lim GRS et al. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study. Cancers (Basel) 13(6), 1308 (2021).
  MedlineGoogle Scholar
• 159. Takada S, Murooka H, Tahatsu K et al. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer. Asian Pac. J. Cancer Prev. 23(2), 695–701 (2022).
  Medline CASGoogle Scholar
• 160. Kizawa R, Kuno M, Washino S et al. 142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: musashino study-irAE. Ann. Oncol. 33, S1488 (2022).
  Google Scholar
• 161. Khan S, Khan SA, Luo X et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br. J. Cancer 120(1), 63–68 (2019).
  Medline CASGoogle Scholar
• 162. Tahir SA, Gao J, Miura Y et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl Acad. Sci. USA 116(44), 22246–22251 (2019).
  Medline CASGoogle Scholar
• 163. Les I, Martínez M, Narro A et al. Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. Ann. Med. 53(1), 762–769 (2021).
  Medline CASGoogle Scholar
• 164. Barth DA, Stanzer S, Spiegelberg J et al. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Cancer Med. 11(16), 3074–3083 (2022).
  Medline CASGoogle Scholar
• 165. Bukhari S, Henick BS, Winchester RJ et al. Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep. Med. 4(1), 100868 (2023).
  Medline CASGoogle Scholar
• 166. Kobayashi T, Nagata M, Ikehata Y et al. T-Cell Receptor Repertoire as a Predictor of Immune-Related Adverse Events in Renal Cell Carcinoma. Curr. Issues Mol. Biol. 45(11), 8939–8949 (2023).
  Medline CASGoogle Scholar
• 167. Liguori L, Luciano A, Polcaro G et al. Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series. Biomedicines 11(11), 2974 (2023).
  MedlineGoogle Scholar
• 168. He S, Wang L, Sun Y, Du H, Yu X. Case Report: successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer. Front. Immunol. 14, 1270828 (2023).
  Medline CASGoogle Scholar